Literature DB >> 35150632

Wastewater surveillance: an effective and adaptable surveillance tool in settings with a low prevalence of COVID-19.

Beverley J Paterson1, David N Durrheim2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35150632      PMCID: PMC8828367          DOI: 10.1016/S2542-5196(22)00009-2

Source DB:  PubMed          Journal:  Lancet Planet Health        ISSN: 2542-5196


× No keyword cloud information.
As Christopher McMahan and colleagues note in their Article, wastewater surveillance of SARS-CoV-2 fills an important surveillance gap left by incomplete individual testing. Everyone defecates but not everyone gets tested for SARS-CoV-2. The key purpose of surveillance is to provide data for informed policy making. We commend the authors for addressing the difficult question of how to establish a quantitative value for a community's viral load in a setting with a high prevalence of COVID-19, and then for proposing a method for communicating results to policy makers and the public. Most literature reporting wastewater surveillance discusses its application in settings with a high prevalence of COVID-19—particularly to track trends and identify hotspots—and McMahan and colleagues add to this literature. However, in a setting with a low prevalence of COVID-19, such as Australia experienced for much of the first 21 months during the pandemic, wastewater surveillance of SARS-CoV-2 unexpectedly became a core epidemiological indicator supporting policy making, with the Australian Government Department of Health working with states and territories to coordinate wastewater testing efforts. Throughout 2020 until September, 2021, Australia's pandemic response focused on aggressive suppression of community transmission, with a requirement to rapidly detect all SARS-CoV-2 infections and to ensure no unrecognised chains of transmission in the community. Wastewater surveillance of SARS-CoV-2 was used to systematically detect viral RNA fragments in wastewater, primarily as an early warning system of local viral introduction and transmission (table 1 ). This action was designed to complement other forms of surveillance, particularly individual testing, informing targeted action for public health, including enhanced capacity for individual testing and public health messaging following local detections.
Table 1

Phases of SARS-CoV-2 wastewater surveillance in Australia from January to September, 2021

Early wastewater surveillance phaseEstablished wastewater surveillance phase
TimeframeJanuary to May, 2021June to September, 2021
Australian contextNational suppression strategy; limited or targeted access to vaccines; quarantine and isolation; testing and contact tracing; lockdowns and border controlsNational four-point response plan moving from current suppression strategy to a post-vaccination phase, focused on prevention of severe outcomes; progressive vaccination of eligible population; quarantine and isolation; testing and contact tracing; progressive restrictions, lockdowns, and border controls
COVID-19 situationFew and limited outbreaks; small numbers of positive cases; limited transmission; limited cross-border incursions; most outbreaks linked to overseas arrivalsPresence of delta (B.1.617.2) variant; less controlled outbreaks; multiple outbreaks within states; cross-border incursions; multiple states affected; most outbreaks linked to domestic cases; more unexplained cases in previously unaffected areas; New South Wales cases peaked at >800 cases per day
Surveillance strategyEarly and initial implementation and trialling in jurisdictions; non-standardised approaches across jurisdictions; no national reporting; development of protocols from environmental health and wastewater authorities; supplemented traditional surveillance systems; sophistication of systems varied widely across jurisdictions; catchments primarily in urban settings, with some regional catchmentsImplementation in all jurisdictions; development of wastewater surveillance protocols (including interpretation, investigation, and public health action); discussion of national standards and reporting; adaptive surveillance system supplementing traditional surveillance systems
IssuesLimited understanding of sensitivity and specificity of wastewater surveillance; difficulty interpreting viral loads; scarce evidence supporting that early detection through wastewater surveillance helped to identify positive casesFrequency and timeliness of sampling and results
BenefitsCommunity-wide screening without any behavioural changes required from the general population; pooled population sample to establish the presence or absence of SARS-CoV-2 in a defined community; reduced biases seen with clinical testingCommunity-wide screening without any behavioural changes required from the general population; pooled population sample to establish the presence or absence of SARS-CoV-2 in a defined community; reduced biases seen with clinical testing; adaptive surveillance system could rapidly sample targeted populations; provided added confidence for policy decisions; showed geographical spread and community burden of the virus
Phases of SARS-CoV-2 wastewater surveillance in Australia from January to September, 2021 The benefits of wastewater surveillance are found in its simplicity, which allows for community-wide screening without any behavioural changes from the general population (table 1). Therefore, the biases seen with clinical testing are minimised—ie, everyone uses the toilet and shower but not everyone gets tested. Additionally, wastewater surveillance assists with epidemiological investigation, helping to identify at-risk locations visited by individuals who test positive for SARS-CoV-2 and providing a pooled population sample to establish the presence or absence of SARS-CoV-2 in a community with a defined low prevalence. The importance of this surveillance strategy increased in 2021 when the delta (B.1.617.2) and omicron (B.1.1.529) variants disrupted Australia's previously successful public health response to the pandemic (table 2 ). The transmission of these variants proved to be far more difficult to control than the earlier ancestral and alpha (B.1.1.7) variants, and required adaptive surveillance systems to support decision making. Despite initial scepticism in Australia, this surveillance strategy has become embedded as a key component of the public health response in a setting with a low prevalence of COVID-19.
Table 2

Application of SARS-CoV-2 wastewater surveillance to policy making at different governmental levels in Australia

Early wastewater surveillance phase
Established wastewater surveillance phase
Policy implicationsPublic health actionPolicy implicationsPublic health action
Local levelEarly warning systemContinuation of existing public health strategies; supplementary confirmation of presence or absence of positive cases; targeted public health messaging encouraging symptomatic people to get testedHighlights new areas of concern; detects viral shedding after release from isolation; identifies multiple chains of infection and proves cessation of local transmission; allows for epidemiological investigation to identify at-risk locationsTargets public health messaging; supplementary confirmation of presence or absence of positive cases; identifies at-risk locations; targeted public health messaging encourages symptomatic people to get tested
State levelEpidemiological assessment; supplementary confirmation of presence or absence of positive cases in communities, regions, and statesTargeted messaging and testing (new testing sites and laboratory surge); implementation or lifting of lockdownsLeading indicator; indicates geographical spread of the virus; targets delivery of vaccinesTargeted messaging and testing (new testing sites and laboratory surge); restriction of travel to regional or remote communities; implementation or lifting of lockdowns
National levelContributes to epidemiological and risk assessmentsAdapting national responsesContributes to epidemiological and risk assessmentsAdapted national responses, including vaccination strategy
Other jurisdictionsContributes to daily risk assessmentsImplementation of controlled border arrangements; identification of high-risk locations; response measures in high-risk areasContributes to daily risk assessments of possible incursions from other states; implementation of controlled border arrangementsImplementation of controlled border arrangements; response measures in high-risk areas

Policy implications and public health actions applicable to other settings with a low prevalence of COVID-19.

Application of SARS-CoV-2 wastewater surveillance to policy making at different governmental levels in Australia Policy implications and public health actions applicable to other settings with a low prevalence of COVID-19. We declare no competing interests.
  1 in total

1.  COVID-19 wastewater epidemiology: a model to estimate infected populations.

Authors:  Christopher S McMahan; Stella Self; Lior Rennert; Corey Kalbaugh; David Kriebel; Duane Graves; Cameron Colby; Jessica A Deaver; Sudeep C Popat; Tanju Karanfil; David L Freedman
Journal:  Lancet Planet Health       Date:  2021-12
  1 in total
  2 in total

1.  An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques.

Authors:  Patrick J Madden; Yanique Thomas; Robert V Blair; Sadia Samer; Mark Doyle; Cecily C Midkiff; Lara A Doyle-Meyers; Mark E Becker; Muhammad S Arif; Michael D McRaven; Lacy M Simons; Ann M Carias; Elena Martinelli; Ramon Lorenzo-Redondo; Judd F Hultquist; Francois J Villinger; Ronald S Veazey; Thomas J Hope
Journal:  bioRxiv       Date:  2022-03-23

2.  An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques.

Authors:  Patrick Madden; Yanique Thomas; Robert Blair; Sadia Samer; Mark Doyle; Cecily Midkiff; Lara Doyle-Meyers; Mark Becker; Shoaib Arif; Michael McRaven; Lacy Simons; Ann Carias; Elena Martinelli; Ramon Lorenzo-Redondo; Judd Hultquist; Francois Villinger; Ronald Veazey; Thomas Hope
Journal:  Res Sq       Date:  2022-04-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.